Clinical trial · Interventional
Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors
Phase I Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors
NCT01018966CI-TRIAL-00025679completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the DLT, MTD and recommended Phase II dose of ixabepilone in Japanese patients with solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ixabepilone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Ixabepilone
- interventionNames
- Drug: Ixabepilone
Primary outcomes (1)
- measure
- To establish the maximum tolerated dose (MTD), and a recommended Phase II dose of Ixabepilone when administered every three weeks by assessing status of treatment, dose intensity, and dose-limiting toxicities (DLT)
- timeFrame
- 3-week treatment cycles until unacceptable toxicity
Secondary outcomes (3)
- measure
- To evaluate safety by assessing adverse events. Toxicity will be evaluated according to the Common Toxicity Criteria Version 3.0 (CTC). Response will be evaluated according to the RECIST (Response Evaluation Criteria in Solid Tumors) criteria
- timeFrame
- 3-week treatment cycles
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 20 years or older * Histologically or cytologically confirmed diagnosis of adenocarcinoma Solid tumors Exclusion Criteria: * Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≥2
References
Publications (0)
Data not yet available
No reference posted for this study.